OncLive Insights

Expert Nicole Lamanna, MD, reviews the clinical evolution of targeted therapies in in B-cell malignancies, highlighting the latest data in CLL to be presented at the upcoming ASH 2023 annual congress.

Following ESMO 2023, a panel of experts on bladder cancer review recent updates and discuss the evolving treatment landscape, with a focus on non–muscle invasive bladder cancer.

Expert oncologists reflect on the evolving treatment paradigm for KRAS-mutated metastatic NSCLC with insight into data from ESMO 2023 and surrounding meetings, discussing targeted therapies and future perspectives in clinical practice.

Experts explore the transformative impact of CAR T-cell therapy on lymphoma treatment, covering mechanisms of action, first-line applications, and ongoing challenges.

Expert oncologists discuss the role of molecular genotyping in metastatic nonsquamous NSCLC in the context of of latest clinical research and consider its impact on treatment selection.

Discover the latest advancements and challenges in the treatment of endometrial cancer, from therapeutic breakthroughs to the importance of diverse clinical trial enrollment, presented by leading experts in gynecologic oncology.

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss the treatment landscape for patients with advanced non–small cell lung cancer and the emerging role of targeting HER3.

Experts discuss the assessment of liver function in patients with hepatocellular carcinoma (HCC) while considering key data from recent clinical trials.

A panel of experts discusses the current landscape of multi-cancer early detection, addressing its potential to broaden access and improve cancer screening, emphasizing the importance of clinical trials and equitable healthcare distribution.

A panel of experts in the field of lower-risk myelodysplastic syndrome discusses current treatment paradigms, reviews clinical trial data, and provides insight on the evolving treatment landscape.

Ramez Eskander, MD, and Krishnansu Tewari, MD, discuss the evolving treatment landscape in the management of advanced or recurrent endometrial cancer.

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, discuss their approaches to the treatment and management of patients with HR-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC) in clinical practice.

Expert physicians delve into the latest data and strategies for managing newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Expert oncologists review data presented at recent conferences and discuss current multidisciplinary strategies for the treatment of patients with HR+/HER2- breast cancer.

John Mascarenhas, MD, and Joe Scandura, MD, PhD, discuss recent advances in the treatment of polycythemia vera (PV) and the impact on clinical practice.

A multidisciplinary team from Dana-Farber Cancer Institute discusses their approach to the care of patients with graft versus host disease.

Expert oncologists review updates in the treatment of small cell lung cancer that were presented at key conferences in 2022 and discuss data in the context the current treatment landscape.

Experts from the John Theurer Cancer Center reflect on the real-world management of patients with myelofibrosis at their institution.

Expert oncologists reflect on the state of molecular testing in non–small cell lung cancer and how it informs the management of patients with uncommon EGFR mutations.

In this series, we will discuss recent advances in the treatment of HR+ breast cancer. We will review two patient cases and discuss our treatment approach to illustrate how we are incorporating recent trial data into our clinical practice.

Key opinion leaders in the field of follicular lymphoma management center discussion on patient cases to review the evolving treatment paradigm of relapsed/refractory disease.

Thought leaders review the impact of myelosuppression in patients undergoing chemotherapy for SCLC as well as the role of supportive care in treatment.

Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review recent clinical data and discuss the current state of fertility preservation in premenopausal patients with breast cancer.

Experts discuss the evolving treatment landscape in advanced or recurrent endometrial cancer. They review the latest updates in clinical research, highlighting non-chemotherapy approaches and their impact on treatment selection.

Expert oncologists review the current treatment landscape of biliary tract cancers and consider how they would apply data from clinical trials to their own practice.

Two expert oncologists review the standard-of-care and unmet needs in the treatment of lower-risk Myelodysplastic Syndromes [MDS]. They discuss emerging data on novel therapies and consider their impact on the treatment landscape for patients with lower-risk MDS.

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, discuss the role of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and review the various biomarkers for targeted therapy.

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the use of Bruton tyrosine kinase (BTK) inhibitors for the treatment of relapsed/refractory mantle cell lymphoma.

Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide insights on treating patients with advanced ovarian cancer and the evolving treatment landscape.

Expert panelists from the UT Southwestern Medical Center review real world patient cases of renal cell carcinoma to illustrate recent clinical data and exhibit how it has been applied at their institution.